APLIF News and Press, Appili Therapeutics Inc From 06/29/22

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the fiscal year ended Mar...

Appili Therapeutics (OTCQX:APLIF) has announced an overnight marketed public offering of units. The units consists of Class A common shares and Class A common share purchase warrants. Terms of the offering, including pricing, are yet to be determined. Net proceeds will be used primarily for w...

Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced that Stéphane Paquette, Vice President, Corporate Development, will present at...

Topical formulation of paromomycin ATI-1801 already shown to be safe and effective against the disfiguring disease in Phase 3 study ATI-1801 may be eligible for tropical disease priority review voucher if approved by FDA Appili Therapeutics Inc. (TSX: APLI; OTCQX: AP...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious di...

NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the March 10 th Life Sciences Investor Forum are now available for on-demand viewing. REGISTER OR LOGIN NOW ...

Company to provide update on drug development pipeline including recently announced US Department of Defense funding for biodefense vaccine candidate ATI-1701 Presentation scheduled for 2:30 pm ET on Thursday, March 10, 2022 HALIFAX, Nova Scotia, March 09, 2022 (GL...

NEW YORK, March 08, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Investor Forum on March 10 th . This virtual event will showcase live company presentations and intera...

Appili Therapeutics (OTCQX:APLIF) will get $10M funding from the U.S. Department of Defense (DOD) to advance its biodefense vaccine candidate ATI-1701 to prevent infection with Francisella tularensis, a type of aerobic bacteria and the causative agent of tularemia. The company said ...

Funds to advance ATI-1701 to IND submission Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced that the U.S. Departme...